A few notes on how it's structured so you can present it confidently: Slides 2 and 13 bookend the argument with the same framing — since ketamine can only tie on efficacy, the debate is decided on tolerability and monitoring, where opioids clearly lead. Repeating it at open and close is a deliberate rhetorical device. Slides 4–6 are your tolerability pillar (predictability → reversibility → titratability), with the naloxone/no-antidote contrast on Slide 5 as your single strongest point. Slides 7–8 are your monitoring pillar, built on the asymmetry: opioids have both an early-warning system (PRODIGY, capnography) and a reversal agent, while ketamine demands heavier monitoring for effects that cannot be reversed. Slides 10–12 handle the marquee trials, rebuttals, and one honesty caveat — pre-empting the opponents' best points makes you more credible under cross-examination.
A few notes on how it's structured so you can present it confidently:
Slides 2 and 13 bookend the argument with the same framing — since ketamine can only tie on efficacy, the debate is decided on tolerability and monitoring, where opioids clearly lead. Repeating it at open and close is a deliberate rhetorical device.
Slides 4–6 are your tolerability pillar (predictability → reversibility → titratability), with the naloxone/no-antidote contrast on Slide 5 as your single strongest point.
Slides 7–8 are your monitoring pillar, built on the asymmetry: opioids have both an early-warning system (PRODIGY, capnography) and a reversal agent, while ketamine demands heavier monitoring for effects that cannot be reversed.
Slides 10–12 handle the marquee trials, rebuttals, and one honesty caveat — pre-empting the opponents' best points makes you more credible under cross-examination.
Created using ChatSlide
This presentation explores the debate on pain management, advocating for opioids over ketamine. It begins by establishing the efficacy of opioids as the baseline, highlighting that ketamine achieves equivalence but not superiority. The case is built on the predictability of opioid adverse effects, detailing dose-dependent patterns and specific side effect rates. Finally, it tests the argument by addressing the neuropsychiatric harms associated with ketamine, presenting data on increased risks...